Giant cell arteritis is a systemic vasculitis and careful ... In a 2001 meta-analysis that included 941 biopsy proven cases of GCA, 4% of those with positive biopsies had "normal" ESRs.

Patients with giant cell arteritis have a greater risk for aortic complications than those with polymyalgia rheumatica.

Findings showed 46.4% of patients treated with upadacitinib 15 mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has ...

The FDA has approved the Janus kinase inhibitor upadacitinib for the treatment of giant cell arteritis in adults, the first ...

The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA). The approval follows the recent marketing ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

The term giant cell arteritis (GCA) reflects the pathological feature seen on biopsy of involved vessels and is more inclusive of the variable presentations of this disease (Figure 1).

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.

The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA). The approval follows the recent marketing ...